Synthetic Biology Market Size, Growth, Key Players and Forecast 2026-2034

According to IMARC Group, the global synthetic biology market size reached USD 21.4 Billion in 2025 and is projected to reach USD 72.4 Billion by 2034, expanding at a CAGR of 14.09% during 2026–2034. This robust synthetic biology market growth reflects accelerating adoption of gene-editing tools such as CRISPR-Cas9, rising investment in engineered therapeutics, and the growing use of synthetic organisms across healthcare, agriculture, and industrial biomanufacturing.

Synthetic Biology Industry Overview

Synthetic biology is a multidisciplinary field that combines biology, engineering, computer science, and chemistry to design and construct new biological parts, devices, and systems, or to redesign existing natural biological systems for useful purposes. Unlike traditional biotechnology, which primarily observes and modifies existing organisms, synthetic biology treats genetic material as a programmable substrate, enabling the creation of entirely new biological functions.

Synthetic biology is deployed across a broad continuum of use cases:

• Healthcare and therapeutics: Gene therapies, synthetic vaccines, engineered cell therapies, and precision diagnostics
• Drug discovery and research: Biomarker validation, disease modeling, and functional genomics using synthetic DNA
• Agriculture: Biotech crops engineered for pest resistance, yield improvement, and climate resilience
• Industrial biomanufacturing: Bio-based chemicals, enzymes, and specialty materials produced through engineered microbial pathways
• Energy and sustainability: Biofuels and bioplastics designed as lower-carbon alternatives to petroleum-based products

Global Synthetic Biology Market Size & Key Statistics

Below are the key statistics drawn from IMARC Group’s comprehensive Synthetic Biology Market Report:

Key Market Drivers & Synthetic Biology Market Trends in 2026

Several powerful forces are shaping the industry and reinforcing sustained synthetic biology market growth expectations across global healthcare, agriculture, and industrial end markets:

1. Advancements in Gene Editing Technologies

Precision gene-editing tools such as CRISPR-Cas9 are enabling researchers to design, edit, and engineer DNA sequences with exceptional accuracy, facilitating the creation of intricate synthetic organisms tailored to specific functions. This capability is opening new avenues in gene therapy and the development of bioengineered organisms capable of producing valuable compounds such as enzymes and biofuels, directly fueling market expansion.

2. Rising Demand for Sustainable, Bio-Based Solutions

Industries are increasingly turning to synthetic biology to reduce environmental impact, from bioplastics extracted from renewable resources to biofuels with lower carbon emissions. Engineered microbes are also being used for bioremediation, helping detoxify contaminants and address pressing ecological challenges, reinforcing synthetic biology’s role in the broader sustainability transition.

3. Expansion of Precision Medicine and Engineered Therapeutics

The increasing use of synthetic biology for drug discovery, personalized medicine, and therapeutic development — including cancer treatments and synthetic vaccines — is propelling growth. Engineered cell therapies and gene-based treatments are enabling more precise, patient-specific interventions with improved outcomes.

4. Integration of AI and Machine Learning in Bio-Design

Artificial intelligence and machine learning tools are accelerating the design process for synthetic biology applications. Predictive modeling, automated data analysis, and streamlined pathway design are improving experimental efficiency and shortening development timelines for new synthetic constructs.

5. Collaborative Research Ecosystem and Rising Investment

Collaboration between academia, industry, and government is accelerating innovation. Government-backed research funding, such as the UK’s Synthetic Biology for Growth program, alongside rising venture capital investment in biotechnology startups, is injecting vital capital into the field and turning early-stage research into commercial products.

6. Supportive Government Policy and Regulatory Frameworks

Governing bodies worldwide are recognizing the strategic potential of synthetic biology and implementing policies to support its development, including dedicated research funding, streamlined regulatory pathways, and initiatives promoting bio-manufacturing and biosecurity.

7. Novel Consumer and Industrial Applications

Beyond healthcare and agriculture, synthetic biology is enabling innovative consumer products that merge genetic engineering with everyday use cases — such as bioluminescent ornamental plants — highlighting the technology’s expanding commercial reach and public interest.

Key Market Segmentation

By Product

Oligonucleotide/oligo pools and synthetic DNA hold the largest product share, around 35.5% in 2025. This segment is driven by its widespread application in gene synthesis, therapeutic development, and biotechnology research — oligonucleotides are critical for PCR, sequencing, and gene editing, while synthetic DNA supports the creation of customized genetic constructs. Rising adoption of CRISPR-Cas9 and growing demand for synthetic genes in personalized medicine and vaccine development continue to strengthen this segment, alongside Enzymes, Cloning Technologies Kits, Xeno-Nucleic Acids, and Chassis Organism.

By Technology

PCR technology is the largest technology segment, with a market share of 30.3% in 2025. PCR is pivotal in synthetic biology, offering precise amplification of specific DNA sequences essential for cloning, gene editing, and functional genomics. Recent innovations, including digital and real-time PCR, are enhancing sensitivity, efficiency, and speed, making the technique indispensable in diagnostics, biomanufacturing, and high-throughput screening. Other technologies covered include NGS Technology, Genome Editing Technology, and Bioprocessing Technology.

By Application

Healthcare accounts for the majority of the market, around 57.5% in 2025, spanning both Clinical (gene therapies, synthetic vaccines, engineered cell therapies) and Non-Clinical/Research (drug discovery, functional genomics, disease modeling) use cases. Non-healthcare applications — including Biotech Crops, Specialty Chemicals, Bio-Fuels, and other industrial uses — represent a fast-growing complementary segment as sustainability commitments expand demand for bio-based alternatives.

Regional Synthetic Biology Market Analysis

North America accounted for the largest share of the global synthetic biology market, holding over 41.8% in 2025, underpinned by sophisticated biotechnology capabilities, established academic and research institutions, and a strong venture capital ecosystem supporting commercialization. The United States in particular benefits from cutting-edge research facilities and an expanding focus on precision medicine and engineered therapeutics.

Asia Pacific is emerging as a fast-growing regional market, supported by government funding for research and development, expanding gene-editing tool availability, and rising agricultural and healthcare demand across China, India, and Japan.

Leading Players in the Global Synthetic Biology Industry

Key players in the synthetic biology market are focusing on expanding their portfolios through research operations, partnerships, and acquisitions, while investing in innovative gene-editing tools, synthetic DNA technologies, and advanced bioengineering platforms. Companies covered in the IMARC Group report include:

• Agilent Technologies Inc.
• Amyris Inc.
• Codexis Inc.
• Danaher Corporation
• Eurofins Scientific
• GenScript Biotech Corporation
• Illumina Inc.
• Merck KGaA
• New England Biolabs
• Synthego Corporation
• Thermo Fisher Scientific Inc.
• Twist Bioscience
• Viridos Inc.

In 2024, Integrated DNA Technologies (IDT) launched Rapid Genes, a next-generation gene synthesis solution offering NGS-verified clonal genes delivered in as little as five business days — accelerating drug discovery through ready-to-use circular DNA with transparent pricing and expanded manufacturing capabilities.

Latest Synthetic Biology Market Industry Developments

May 2024 – Integrated DNA Technologies (IDT)

IDT expanded its synthetic biology operations with the opening of a new 25,000 sq. ft. site in Coralville, Iowa. The two-story facility is dedicated to manufacturing IDT’s synthetic biology products, reinforcing the company’s production capacity for gene synthesis solutions.

December 2023 – Seattle Hub for Synthetic Biology

The Allen Institute, the Chan Zuckerberg Initiative, and the University of Washington announced the launch of the Seattle Hub for Synthetic Biology, a landmark collaboration aimed at building new technologies to record the history of cells over time.

2024 – U.S. National Science Foundation

The NSF awarded a USD 15 Million grant to establish the iBioFoundry at the University of Illinois Urbana-Champaign, combining synthetic biology, AI, and robotics to advance biomanufacturing and serve as a collaborative hub for researchers and industry stakeholders.

2023 – UK Research Councils

The Synthetic Biology for Growth program was established following UK government recommendations on synthetic biology research and investment, with a budget of USD 126.48 Million allocated to the initiative.

About Us

IMARC Group is a leading global market research company providing data-driven insights and expert consulting services to businesses seeking to achieve their strategic objectives. With a multi-disciplinary team of industry experts, IMARC delivers thorough, reliable market intelligence across sectors including Healthcare, Technology, Chemicals, Energy, Food & Beverages, and more.

Contact Us

IMARC Group

United States: +1-201-971-6302

India: +91-120-433-0800

United Kingdom: +44-753-714-6104

Article source: https://article-realm.com/article/Health-Fitness/85156-Synthetic-Biology-Market-Size-Growth-Key-Players-and-Forecast-2026-2034.html